Roche (RHHBY) unveiled its proprietary, breakthrough sequencing by expansion technology, establishing a new category of next-generation ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price ...

A pioneering team at St Jude Children's Research Hospital in the US say they successfully treated a child diagnosed with SMA ...